CorMedix, Inc.(NASDAQ : CRMD)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|VRTX||Vertex Pharmaceuticals, Inc.||0.27%||282.54||1.9%||$481.11m|
|GILD||Gilead Sciences, Inc.||-0.36%||61.59||1.0%||$473.71m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.37%||588.93||2.6%||$469.91m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.84%||3.77||0.7%||$263.54m|
|CRSP||CRISPR Therapeutics AG||3.11%||62.66||0.6%||$165.07m|
|BMRN||BioMarin Pharmaceutical, Inc.||0.68%||83.43||4.2%||$116.97m|
|EXAS||EXACT Sciences Corp.||2.29%||40.29||17.7%||$93.01m|
|IOVA||Iovance Biotherapeutics, Inc.||2.90%||11.36||0.0%||$90.66m|
CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.